Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This is a study in patients with moderate to severe chronic plaque psoriasis.All the
participants will be randomized into three groups, high-dose UC-MSCs, low-dose UC-MSCs, or
methotrexate group.This study is designed to prove that UC-MSCs is safe and effective.